Cargando...
Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men
Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical mo...
Gardado en:
| Publicado en: | Sci Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930243/ https://ncbi.nlm.nih.gov/pubmed/33658534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-83974-8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|